Status:
COMPLETED
Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations
Lead Sponsor:
The University of Texas Health Science Center, Houston
Conditions:
Multiple Sclerosis (MS)
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
This pilot study is designed as a prospective cohort study to determine whether standard subcutaneous (SQ) Highly-Purified (HP) Acthar Gel 14 days is superior to SQ HP Acthar Gel 5 days in the treatme...
Detailed Description
Evaluations and treatment will be administered as an outpatient in the Neurology Clinic. Each subject will be seen for MS relapse or exacerbation in the Neurology Clinic during a routine or semi-emerg...
Eligibility Criteria
Inclusion
- Adult male or female subjects with MS having a relapse (attack) or exacerbation of MS. Acute symptomatic exacerbation of MS present for \> 24 hours and \< 14 days at screening with new or worsening symptoms, and with signs referable to the symptoms in the absence of a fever or active infection.
- Diagnosis of a relapsing forms of multiple sclerosis before randomization as determined by Poser or McDonald Criteria (standard MS diagnostic criteria).
- Expanded disability status scale (EDDS) between 2 and 6.5, inclusive at entry.
- Episodes include study neurologist or neuro-ophthalmologist diagnosed: acute optic neuritis, cerebellar, brainstem dysfunction, myelitis, focal cerebral, and/or definitive focal sensory dysfunction.
- New objective clinical finding other than the sensory exacerbation or the bowel/bladder signs alone. Sensory deficits alone will not qualify except for optic neuritis.
- Subjects may continue on their current immunomodulation therapy such as interferons, glatiramer acetate, gilenya or natalizumab.
- Identified patients must be between the ages of 18 and 55 years, inclusive.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion
- Subjects who are pregnant, or nursing.
- Any patients treated with systemic corticosteroid use within one month of the index episode at screening.
- Prior use of immunosuppressive treatments within 90 days of index episode (mitoxantrone, azathioprine, Cellcept, IVIg) or plasmapheresis.
- Unable to perform timed 25 foot walk (ambulation Index), 9 HPT (9 hole peg test), PASAT (Paced Auditory Serial Addition Test) 3.
- Peripheral or cranial neuropathy as sole problem of acute episode.
- Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
- History of any significant cardiac, gastrointestinal, hepatic, pulmonary, or renal disease; immune deficiency; or other medical conditions that would preclude corticosteroid therapy.
- Subjects with clinical diagnosis of scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, hypertension, or sensitivity to proteins of porcine origin.
- Primary Progressive Multiple Sclerosis (PPMS) (MS without attacks). -
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT01888354
Start Date
April 1 2013
End Date
August 1 2014
Last Update
September 16 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
The MS Center at the Neurology Center in Southern California
Oceanside, California, United States, 92056
2
The University of Texas-Houston Neurology Clinic
Houston, Texas, United States, 77030